Medimaps to scale Asian sales through South Korea

Osteoporosis is a condition of primary concern among ageing patient populations. Patients at risk for osteoporotic fractures often receive a Bone Mineral Densitometer (BMD) assessment, which only measures bone quantity but not bone quality. Swiss digital health startup Medimaps Group specialising in image processing software applications based on patented multi-purpose technology with artificial intelligence capabilities, developed TBS iNsight™ (Osteo) to support clinical practice worldwide in osteoporosis.

TBS iNsight works alongside BMD and clinical risk factors to analyse bone micro-architecture to assess bone quality. Within moments, the software application provides practitioners with an easy-to-interpret score to quickly identify and classify patients’ fracture risk and implement a course of intervention. Medimaps technology utilises the same images acquired for BMD assessment (but also digital x-ray or projected CT images). Patients are not exposed to additional radiation, and TBS integrates seamlessly into a physician’s clinical workflow to provide a completed structured report.

Industry’s gold standard
TBS iNsight™ (Osteo) has become the new gold standard for bone texture assessment in routine clinical practice. It has also gained international recognition with more than 900 peer-reviewed scientific publications and is included in many guidelines and used by more than 30,000 physicians worldwide, including leading healthcare institutions.

Third largest DXA scanning equipment launches TBS in Asia
Medimaps has obtained a CE 2797 mark for TBS iNsight™, an FDA 510(k) clearance in the US, and it is cleared in more than 60 countries worldwide, including Japan and South Korea, where it has already sold products. TBS is also now reimbursable in the US and some European countries, while the company works towards reimbursement in Japan and Korea. TBS is recommended for use by many local, national, and international medical societies such as in Switzerland, France, Italy, Germany, and Spain, as well as in the United States, China, and Japan.

The startup partnered with OsteoSys Co., Ltd, a South Korea-based company manufacturing bone densitometer devices to treat and diagnose osteoporosis through a wide range of body and peripheral DXA scanning offerings. The partnership aims to bring TBS iNsight™ on OsteoSys’ Primus Whole Body DXA, their high-end DXA scanning product. The agreement expands worldwide access to Medimaps’ technology to clinicians in Southeast Asia, Europe, and South America countries. Financial terms were not disclosed.

Medimaps is based in Geneva with offices in France and the United States and over 55 people worldwide.

(Press release/RAN)